Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biopsy- and biology-driven optimization of dabrafenib and trametinib targeted therapy in advanced BRAF V600-mutant melanoma
2012-005569-10Phase 2Terminated
- Sponsor
- Universitätsmedizin Essen
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of dabrafenib + trametinib and trametinib in cutaneous melanoma (CM) and melanoma (2 cohorts), sponsored by Universitätsmedizin Essen. Primary endpoint: Correlation of clinical response at week 8 with molecular biopsy results. Started Apr 2013; status: terminated.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
cutaneous melanoma (CM)melanoma
Beyond the preview
Go deeper on 2012-005569-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005569-10.